Notícias Lantern Pharma Inc - LTRN | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Lantern Pharma Inc (LTRN)
Lantern Pharma Inc (LTRN) Notícias

Lantern Pharma Inc (LTRN)

4,95

0,14

(2,91%)

Fechado 01 Fevereiro 6:00PM

Atrasado por 15 minutos

4,98

0,03

(0,61%)

Após o horário de negociação: 9:59PM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Form 4 - Statement of changes in beneficial ownership of securities

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer

Form 8-K - Current report

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights

Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET

Form 8-K - Current report

Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET

Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma

Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors

2
3
4
Próxima

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições